Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
insight
/
details

Unlocking Precision Psychiatry: The Role of Blood Biomarkers in Mental Health

NextEdge Admin

17 Apr 2024

2 min 57 sec

In the complex landscape of mental health, where mood disorders affect one in four individuals, challenges abound in underdiagnosis and suboptimal treatment, often leading to self-medication and, in severe cases, suicide. The absence of objective tests and the prevailing stigma surrounding mental health contribute to misdiagnosis, exacerbating the crisis. However, a promising shift is occurring with the emergence of blood biomarkers as game-changers in the field.

Pioneering research has identified gene expression biomarkers associated with mood states and suicidality, offering hope for reliable diagnostics and personalized medication matching. Specific single nucleotide polymorphisms (SNPs) serve as indicators of an increased risk of mood disorders, guiding targeted interventions.

Liquid biopsies, which analyze blood, cerebrospinal fluid, or saliva, are revolutionizing neuropsychiatric diagnostics. Blood gene expression analysis reveals molecular mechanisms, while circadian-related biomarkers shed light on sleep disruptions, enhancing early detection and minimizing misdiagnosis risks. Cortisol levels in saliva act as stress-related markers, aiding in understanding and treating conditions like depression. The integration of liquid biopsies into clinical practice heralds a new era of precision psychiatry. These biomarkers not only redefine neuropsychiatric treatment but also inform drug development by uncovering molecular pathways for targeted therapies.

Precision medicine in psychiatry exemplified using low-dose lithium for treating depression and anxiety. In a recent study, researchers focused on patients with depression or anxiety who had a specific genetic marker related to the CACNA1C gene. This gene has long been associated with mental illnesses such as bipolar disorder, schizophrenia, major depression, and anxiety. The study found that patients with this genetic marker who were prescribed low-dose lithium experienced significant improvements in both mood and anxiety symptoms.

These transformative approaches hold the promise of optimal mental health outcomes for individuals, marking a significant leap forward in the quest for effective and personalized psychiatric care.